Despite lower revenue forecasts, analysts see no long-term i...
Despite lower revenue forecasts, analysts see no long-term impact on the business's intrinsic value. Opinions vary, with the most optimistic analyst valuing it at US$112 and the most pessimistic at US$26.00 per share. No changes were made to next year's loss forecasts, but revenue estimates were downgraded. The company's long-term earnings trajectory is deemed more crucial than next year's performance.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are Pretty Bullish On The Stock After Recent Results
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment